EGFR tyrosine kinase inhibitors (TKIs) like Gefitinib have been extensively studied in HNSCC, but again have resulted in low response rates of 11% and, thus, none have been approved by FDA as of 2024 [35]. Here, EGFR is linked to head and neck squamous cell carcinoma.